U.S. markets close in 3 hours 20 minutes
  • S&P 500

    4,152.28
    -33.19 (-0.79%)
     
  • Dow 30

    33,992.96
    -207.71 (-0.61%)
     
  • Nasdaq

    13,851.95
    -200.39 (-1.43%)
     
  • Russell 2000

    2,227.83
    -34.84 (-1.54%)
     
  • Crude Oil

    63.33
    +0.20 (+0.32%)
     
  • Gold

    1,770.50
    -9.70 (-0.54%)
     
  • Silver

    25.74
    -0.37 (-1.42%)
     
  • EUR/USD

    1.2038
    +0.0058 (+0.48%)
     
  • 10-Yr Bond

    1.5910
    +0.0180 (+1.14%)
     
  • GBP/USD

    1.3983
    +0.0143 (+1.03%)
     
  • USD/JPY

    108.0800
    -0.7030 (-0.65%)
     
  • BTC-USD

    55,114.40
    +230.67 (+0.42%)
     
  • CMC Crypto 200

    1,248.47
    -50.49 (-3.89%)
     
  • FTSE 100

    7,000.08
    -19.45 (-0.28%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Calculating The Fair Value Of BioTelemetry, Inc. (NASDAQ:BEAT)

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·6 min read
  • Oops!
    Something went wrong.
    Please try again later.

Today we will run through one way of estimating the intrinsic value of BioTelemetry, Inc. (NASDAQ:BEAT) by estimating the company's future cash flows and discounting them to their present value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward.

Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.

View our latest analysis for BioTelemetry

The calculation

We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars:

10-year free cash flow (FCF) estimate

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Levered FCF ($, Millions)

US$90.2m

US$78.0m

US$71.2m

US$67.3m

US$65.2m

US$64.2m

US$64.0m

US$64.2m

US$64.8m

US$65.7m

Growth Rate Estimate Source

Analyst x2

Analyst x1

Est @ -8.7%

Est @ -5.43%

Est @ -3.13%

Est @ -1.53%

Est @ -0.4%

Est @ 0.38%

Est @ 0.93%

Est @ 1.32%

Present Value ($, Millions) Discounted @ 7.0%

US$84.3

US$68.1

US$58.1

US$51.3

US$46.5

US$42.7

US$39.8

US$37.3

US$35.2

US$33.3

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$496m

We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.2%. We discount the terminal cash flows to today's value at a cost of equity of 7.0%.

Terminal Value (TV)= FCF2030 × (1 + g) ÷ (r – g) = US$66m× (1 + 2.2%) ÷ (7.0%– 2.2%) = US$1.4b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$1.4b÷ ( 1 + 7.0%)10= US$708m

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$1.2b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of US$37.6, the company appears around fair value at the time of writing. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.

dcf
dcf

Important assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at BioTelemetry as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.0%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Moving On:

Whilst important, the DCF calculation ideally won't be the sole piece of analysis you scrutinize for a company. The DCF model is not a perfect stock valuation tool. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For BioTelemetry, we've put together three additional elements you should look at:

  1. Risks: Case in point, we've spotted 4 warning signs for BioTelemetry you should be aware of.

  2. Future Earnings: How does BEAT's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NASDAQGS every day. If you want to find the calculation for other stocks just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.